Edesa BiotechのRPE

Edesa BiotechのRPEは何ですか。

Edesa Biotech, Inc.のRPEは0.00$です。

RPEの定義は何ですか。

従業員1人当たりの収益(RPE)は、収益を組織の従業員の数で割ったものです。

NASDAQのセクタHealth CareにおけるRPEの企業と比べるEdesa Biotech

Edesa Biotechは何をしますか。

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Edesa Biotechと類似のrpe